Fig. 1 · Structure

Documents & Downloads

Bumetanide

Cat. No. A10167 CAS 28395-03-1
Bumetanide is a loop diuretic of the sulfamyl category to treat heart failure.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Bumetanide occupies the extracellular ion-entry vestibule of human NKCC1. In a phospho-activated NKCC1 co-structure, its carboxyl group coordinates a co-occluded K+ ion while the transporter is captured in an outward-open state, supporting inhibition by obstruction of the ion pathway. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

In Vitro Studies

Bumetanide inhibited NKCC1-mediated chloride influx in a HEK293 reporter assay at 100 μM. In a separate HEK293 assay, 10 μM bumetanide also inhibited NKCC2-mediated chloride influx. These experiments support activity at both cotransporters; their treatment concentrations are not interchangeable IC50 values. [1,2]

Bumetanide occupies the extracellular NKCC1 ion pathway

Biochemical assay · Purified full-length human phospho-activated NKCC1, produced in HEK293T/17 SF cells co-expressing WNK1(1–483, S378D), Mo25 and SPAK. [1]

The bumetanide co-structure places the compound in the extracellular vestibule of an outward-open NKCC1. Its carboxyl group coordinates a co-occluded K+ ion. This is structural evidence for occlusion of the transport pathway, not a binding-affinity measurement.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Position of bound bumetanide and K+ in the NKCC1 ion pathwayStructural observation Extracellular vestibule occupancy in an outward-open state; carboxyl group coordinates K+.[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM during membrane preparation and protein purification
Exposure duration
Maintained through purification
Method
Single-particle cryo-EM of the purified bumetanide/NKCC1 complex
Reported limits
No dissociation constant measured by this structural experiment; no supplier lot specified.
Methods and source locations

Compound reported in the paper: Bumetanide; Compound label in the paper: bumetanide

Compound-level evidence for bumetanide; no Adooq lot or formulation validation.

Results: Overall architecture; Two modes of NKCC1 antagonism; Fig. EV2A,B; Fig. EV3B; Methods: expression/purification and EM reconstruction

Position of bound bumetanide and K+ in the NKCC1 ion pathway: Single-particle cryo-EM; interpretation of ligand and ion densities. — Fig. EV2A,B; Fig. EV3B; Results: Two modes of NKCC1 antagonism

Inhibition of NKCC1-mediated chloride influx in HEK293 cells

Cell-based study · HEK293T/17 SF stable cells expressing human Twin-Strep-NKCC1 and membrane-targeted Cl−-sensitive mbYFPQS. [1]

Externally applied bumetanide inhibited the NKCC1-associated fluorescence response to chloride addition. Reporter-only cells were included as a negative control. The concentration-response experiment used four biological repeats with mean ± SD; no exact IC50 is extracted from the plotted curve.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
NKCC1-mediated chloride transportQualitative inhibition Inhibition at 100 μM; concentration-dependent suppression shown (n = 4 biological repeats; mean ± SD for dose-response).[1]

Literature-Reported Treatment Conditions

Treatment concentration
100 μM for inhibitor validation; a concentration-response series is also shown
Exposure duration
Activation-buffer incubation 2–3 h; transport rates derived from the initial 20 s after assay-buffer exchange
Method
Extracellular addition in activation and assay buffers; mbYFPQS fluorescence assay
Reported limits
Vehicle for bumetanide is not specified in the read assay methods. Individual dose-series exposure timing is not separately described.
Methods and source locations

Compound reported in the paper: Bumetanide; Compound label in the paper: bumetanide

Compound-level evidence for bumetanide; no Adooq lot or formulation validation.

Fig. EV1A–D; Methods: Cl− influx assay in HEK293 cells; reagents table

NKCC1-mediated chloride transport: mbYFPQS fluorescence; slopes over the first 20 s after chloride addition; reporter-only negative control. — Fig. EV1A,B; Methods: Cl− influx assay

Bumetanide also inhibits NKCC2-mediated chloride influx

Cell-based study · HEK293 cells transfected with NKCC2 and mbYFPQS, with mock-transfected cells for background subtraction. [2]

Bumetanide at 10 μM inhibited NKCC2-mediated chloride influx relative to DMSO control. ARN23746 was tested in parallel and did not significantly inhibit NKCC2 under these conditions. The bumetanide result limits an NKCC1-selective interpretation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
NKCC2-associated fluorescence decrease after chloride additionDirectional inhibition Significant inhibition at 10 μM versus DMSO (figure: ***p < 0.001); four independent experiments; mean ± SEM presentation.[2]

Literature-Reported Treatment Conditions

Treatment concentration
10 μM
Exposure duration
30 min pretreatment; 20 s baseline followed by 60 s recording after NaCl addition
Method
Cl−-sensitive mbYFPQS assay; final 74 mM NaCl; endpoint uses the final 10 s of normalized fluorescence
Vehicle
0.1% DMSO control
Reported limits
Bumetanide lot and a separate in-vitro supplier are not specified in the read methods.
Methods and source locations

Compound reported in the paper: Bumetanide; Compound label in the paper: Bume

Evidence concerns the named parent compound in the stated assay; no supplier equivalence or Adooq lot validation.

Fig. 2B; Results: Design and Synthesis of NKCC1 Novel Inhibitors; Methods: HEK Cell Culture and Transfection; Cl− Influx Assay

NKCC2-associated fluorescence decrease after chloride addition: Mock-subtracted mbYFPQS response, normalized to DMSO; Kruskal–Wallis test with Dunn’s post hoc test. — Fig. 2B and caption; corresponding Results paragraph; Cl− influx Methods

In Vivo Studies

In adult wild-type and Ts65Dn mice, bumetanide at 0.2 mg kg−1 by intraperitoneal injection increased urine output during a 2 h collection period compared with genotype-matched vehicle controls. This acute peripheral endpoint does not establish brain exposure or neurological efficacy. [2]

Acute bumetanide-induced diuresis in adult mice

Animal study · Adult P60–120 Ts65Dn mice and wild-type littermates, both males and females; separate genotype-matched vehicle controls. [2]

A 0.2 mg kg−1 intraperitoneal dose of bumetanide increased urine output over 2 h in both genotypes. ARN23746, tested as a separate comparator, did not significantly increase urine output. This endpoint demonstrates a peripheral diuretic effect, not brain target engagement or cognitive benefit.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Urine volume collected over 120 minDirection and reported statistical test Increased in WT and Ts65Dn mice versus matched vehicle; two-way ANOVA Ftreatment(2,69) = 10.516, p < 0.001; Tukey post hoc; data shown as mean ± SEM and individual animals.[2]

Conditions shared by the study groups

Route
Intraperitoneal injection
Frequency
One injection immediately before the 2 h urine-collection interval
Treatment course
2 h acute diuresis assessment
Vehicle
DMSO stock diluted in PBS; animal-group description calls the vehicle 2% DMSO in saline.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Wild-type littermates
0.2 mg kg−1
Genotype-matched vehicle-treated mice; ARN23746 was a separate parallel comparator.Urine volume increased significantly relative to genotype-matched vehicle. ARN23746 did not significantly increase urine volume.[2]
Ts65Dn mice
0.2 mg kg−1
Genotype-matched vehicle-treated mice; ARN23746 was a separate parallel comparator.Urine volume increased significantly relative to genotype-matched vehicle. ARN23746 did not significantly increase urine volume.[2]
Wild-type littermates
Model: Adult wild-type littermates of Ts65Dn mice, both sexes, P60–120
Reported limits: Per-group n is displayed as individual points but is not assigned here. Exact saline/PBS wording differs between method subsections. Prior dosing before the acute collection is not separately specified.
Ts65Dn mice
Model: Adult Ts65Dn mice, both sexes, P60–120
Reported limits: Per-group n is displayed as individual points but is not assigned here. Exact saline/PBS wording differs between method subsections. Prior dosing before the acute collection is not separately specified.
Methods and source locations

Compound reported in the paper: Bumetanide; Compound label in the paper: Bume

Evidence concerns the named parent compound in the stated assay; no supplier equivalence or Adooq lot validation.

Fig. 3A,B and caption; Results: Efficacy of the Lead Compound; Methods: Animals, Compound Preparation for In Vivo Experiments, Diuresis Analysis

Urine volume collected over 120 min: Urine collection in individual metabolic cages for 2 h immediately after treatment; no exact group means inferred from graph. — Fig. 3A,B and caption; Diuresis Analysis Methods

Wild-type littermates · Fig. 3A,B and caption; Results: Efficacy of the Lead Compound; Methods: Animals, Compound Preparation for In Vivo Experiments, Diuresis Analysis

Ts65Dn mice · Fig. 3A,B and caption; Results: Efficacy of the Lead Compound; Methods: Animals, Compound Preparation for In Vivo Experiments, Diuresis Analysis

Specifications

Manufacturer Adooq Bioscience
CAS Number 28395-03-1
Formula C17H20N2O5S
Molecular Weight 364.4
Synonyms Bumex
SMILES
CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 67 mg/mL (183.85 mM)
Water Insoluble
Ethanol 33 mg/mL (90.55 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Yongxiang Zhao, Pietro Vidossich, Biff Forbush, et al. Structural basis for human NKCC1 inhibition by loop diuretic drugs The EMBO Journal (2025). PMID: 39875725 DOI: 10.1038/s44318-025-00368-6 Source material
  2. [2] Annalisa Savardi, Marco Borgogno, Roberto Narducci, et al. Discovery of a Small Molecule Drug Candidate for Selective NKCC1 Inhibition in Brain Disorders Chem (2020). PMID: 32818158 DOI: 10.1016/j.chempr.2020.06.017 Source material

Added to your cart

View Cart Checkout
Loading...